Denali Therapeutics Inc (NASDAQ:DNLI) COO Alexander O. Schuth sold 7,500 shares of the stock in a transaction on Friday, January 11th. The stock was sold at an average price of $20.37, for a total transaction of $152,775.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Shares of DNLI stock traded up $0.71 during trading hours on Friday, reaching $20.89. The stock had a trading volume of 321,800 shares, compared to its average volume of 402,188. Denali Therapeutics Inc has a twelve month low of $12.32 and a twelve month high of $25.79. The stock has a market cap of $1.91 billion and a PE ratio of -3.55.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Thursday, November 8th. The company reported ($0.38) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.13). The company had revenue of $1.20 million for the quarter, compared to analyst estimates of $3.00 million. On average, analysts expect that Denali Therapeutics Inc will post -1.28 earnings per share for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the stock. Great West Life Assurance Co. Can acquired a new stake in shares of Denali Therapeutics in the 3rd quarter worth about $161,000. Osborn Williams & Donohoe LLC acquired a new stake in shares of Denali Therapeutics in the 3rd quarter worth about $217,000. Jane Street Group LLC acquired a new stake in shares of Denali Therapeutics in the 3rd quarter worth about $218,000. Man Group plc acquired a new stake in shares of Denali Therapeutics in the 3rd quarter worth about $228,000. Finally, JPMorgan Chase & Co. increased its holdings in shares of Denali Therapeutics by 207.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 10,554 shares of the company’s stock worth $229,000 after acquiring an additional 7,120 shares during the period. 70.52% of the stock is currently owned by institutional investors and hedge funds.

A number of brokerages have weighed in on DNLI. Cantor Fitzgerald reissued a “buy” rating and set a $25.00 target price on shares of Denali Therapeutics in a report on Friday, December 7th. Zacks Investment Research raised shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $22.00 target price on the stock in a report on Thursday, January 3rd. Finally, Janney Montgomery Scott began coverage on shares of Denali Therapeutics in a report on Monday, November 12th. They set a “buy” rating and a $26.00 target price on the stock.

COPYRIGHT VIOLATION WARNING: “Alexander O. Schuth Sells 7,500 Shares of Denali Therapeutics Inc (DNLI) Stock” was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://theolympiareport.com/2019/01/11/alexander-o-schuth-sells-7500-shares-of-denali-therapeutics-inc-dnli-stock.html.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

Featured Story: Trading signals using Bollinger bands

Insider Buying and Selling by Quarter for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.